Navigation Links
Varian Medical Systems to Showcase Radiosurgery Technology for Non-invasive Treatment of Early Stage Inoperable Lung Cancer
Date:5/17/2012

in the body when radiation treatment is indicated. While clinical studies such as those highlighted here may support the effectiveness of Varian's technology when used for radiotherapy or radiosurgery, individual results may vary. There are no guarantees of outcome.


[1] Timmerman R et al. Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer.  JAMA. 2010;303(11):1070-1076. doi: 10.1001/jama.2010.261

[2]Phase III Randomized Study of Sublobar Resection With or Without Brachytherapy Versus Stereotactic Body Radiotherapy in High-Risk Patients With Stage I Non-Small Cell Lung Cancer. Information is available at the NCI website at the following URL: http://www.cancer.gov/clinicaltrials/search/view?cdrid=698986&protocolsearchid=9090456&version=patient.

[3] Palma DA, Senan S, Haasbeek CJ, Verbakel WF, Vincent A, Lagerwaard F. Radiological and clinical pneumonitis after stereotactic lung radiotherapy: a matched analysis of three-dimensional conformal and volumetric-modulated arc therapy techniques. Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):506-13.

[4] Ong CL, Verbakel WF, Cuijpers JP, Slotman BJ, Lagerwaard FJ, Senan S. Stereotactic radiotherapy for peripheral lung tumors: a comparison of volumetric modulated arc therapy with 3 other delivery techniques. Radiother Oncol. 2010 Dec;97(3):437-42

[5] Ong CL, Palma D, Verbakel WF, Slotman BJ, Senan S. Treatment of large stage I-II lung tumors using stereotactic body radiotherapy (SBRT): planning considerations and early toxicity. Radiother Oncol. 2010 Dec;97(3):431-6.

[6] Verbakel WF, Senan S, Cuijpers JP, Slotman BJ, Lagerwaard FJ. Rapid delivery of stereotactic radiotherapy for peripheral lung tumors using volumetric intensity-modulated arcs.  Radiother Oncol. 2009 Oct;93(1):122-4.

'/>"/>

SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... July 31, 2014  According to data released today ... 2015 average monthly Medicare Part D premium is expected ... than was originally projected, the Pharmaceutical Care Management Association ... continues to be a bright spot in American health ... each region and using cutting edge, cost-saving tools like ...
(Date:7/31/2014)... SAN DIEGO , July 31, 2014  Sorrento Therapeutics, ... death of Mr. Amar Singh , Chief Business Officer ... of apparent natural causes on July 30. "Sorrento ... dear friend and colleague. Our immediate thoughts go to Amar,s ... President and Chief Executive Officer. Mr. Singh ...
(Date:7/31/2014)... -- STAAR Surgical Company (NASDAQ: STAA ) ... and delivery systems for the eye today reported revenue ... $20.0 million, a 10% increase over $18.2 million reported ... currency basis, revenues grew 11% during the second quarter ... The effect of foreign currency exchange reduced sales by ...
Breaking Medicine Technology:Sorrento Announces the Unexpected Death of its Chief Business Officer 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31
... 7 ActivBiotics, Inc. today,announced the results ... effect of rifalazil in the treatment of ... The results demonstrated,that treatment for two months ... in a significant improvement in walking distance,claudication ...
... the American Heart Association Scientific Sessions ... 2007 ... Nabi,Biopharmaceuticals (Nasdaq: NABI ) today announced the successful completion,of ... innovative and proprietary investigational vaccine being,developed to treat nicotine addiction ...
Cached Medicine Technology:Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 2Rifalazil Trial (PROVIDENCE-1) Fails to Provide Significant Clinical Benefit in Patients With Peripheral Arterial Disease 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 2Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 3Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 4Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 5Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 6Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months 7
(Date:7/31/2014)... 31, 2014 Hoping to attract new customers ... trust , NutriGold is ready to ship out free ... make taking advantage of this offer fast and easy: ... and Development at NutriGold, "We know that every time customers ... their most precious asset: their own health or the health ...
(Date:7/31/2014)... TN (PRWEB) July 31, 2014 In many ... are required for proper storage of necessary life saving drugs. ... staff. Unfortunately there is still a high number of ambulances ... an EMT who steals the narcotics and even replaces the ... relief receives none. As seen in the case in Baraboo, ...
(Date:7/31/2014)... Niche Profit Classroom, a method and guide ... to provide a blueprint for anyone who is interested in ... prompting an investigative review. , Learn more about ... about the success of the information in this course is ... have stayed effective even through all of the major search ...
(Date:7/31/2014)... United Theological Seminary is pleased to welcome ... and Peter J. Bellini. Both began their teaching duties ... a Director of Non-Degree Programs, Mark Abbott, who begins ... Donne, Assistant Professor of New Testament, received a Ph.D. ... Second Temple Judaism, and Greek courses. His research interests ...
(Date:7/31/2014)... Angeles, CA (PRWEB) July 31, 2014 US ... his practice will now be known as Parsa Mohebi Hair ... has helped hundreds of patients in Southern California and around ... Los Angeles, Beverly Hills and Orange County. These patients achieved ... including many surgical techniques that were perfected by Dr. Mohebi. ...
Breaking Medicine News(10 mins):Health News:NutriGold Launches Product Samples Page for its Supplements 2Health News:NutriGold Launches Product Samples Page for its Supplements 3Health News:New MedixSafe Alert - Ambulances Must Have A Medical Safe, Narcotics Cabinet, or Drug Locker 2Health News:Niche Profit Classroom: Review Exposes Adam Short’s Guide to Building Niche Websites 2Health News:Growing Seminary Welcomes New Faculty 2Health News:US Hair Restoration Becomes Parsa Mohebi Hair Restoration 2
... Today the International and American Associations for Dental Research ... remains the number one journal of 64 journal published in ... new 2009 Five-Year Scientific Impact Factor (SIF) rankings, published by ... the JDR,s Five-Year SIF increased from 3.966 to 4.195. ...
... , ... open to the public, Andy Thomas job seminars teach participants unique personal marketing strategies ... Minutes to a Better Career”; Career counselor Thomas is a former talk show host ... 60 unemployed in attendance, and a drawing will be held for Thomas providing free ...
... DocGreet.com is ... their time and streamline their patient communication, that the company has announced a money back ... ... sure that the services available to Doctors, Physicians and Health Care Providers will monetize their ...
... ... of the Enterprise Architecture Professional Practice Guide and a brochure on Enterprise Architecture as a ... (PRWEB) June ... ,These abstracts provide the enterprise architect,s contract with the public they serve and consist of ...
... colonoscopy is effective and cost-effective when targeted to ... Gastroenterology , the official journal of the ... surveillance colonoscopy could be excessively costly or even ... and utilized practice that has the potential to ...
... Institute (NHLBI), part of the National Institutes of Health, is ... efficacy of red blood cell transfusions vary depending on how ... supports the first large, multi-center, randomized clinical trial to compare ... blood cells that have been stored for shorter or longer ...
Cached Medicine News:Health News:JDR increases its 5-Year SIF and remains number one dental journal of 64 in its category 2Health News:Columbia Extreme Job Makeover Slated for June 26 2Health News:Columbia Extreme Job Makeover Slated for June 26 3Health News:DocGreet Guarantees More Time and Money to Doctors and Health Care Providers 2Health News:Enterprise Architecture -- Breaking Away From The Pack 2Health News:Surveillance colonoscopy should be targeted to high-risk patients 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 2Health News:NHLBI funds research to improve safety of red blood cell transfusions 3Health News:NHLBI funds research to improve safety of red blood cell transfusions 4Health News:NHLBI funds research to improve safety of red blood cell transfusions 5Health News:NHLBI funds research to improve safety of red blood cell transfusions 6Health News:NHLBI funds research to improve safety of red blood cell transfusions 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: